Salmetedur en es it fr

Categoria

Salmetedur Nombres de marca, Salmetedur Analogos

Salmetedur Marca los nombres de mezcla

  • Advair 100 Diskus (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 125 (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 250 (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 250 Diskus (Fluticasone Propionate + Salmeterol Xinafoate)
  • Advair 500 Diskus (Fluticasone Propionate + Salmeterol Xinafoate)
  • Salmetedur Formula quimica

    C25H37NO4

    Salmetedur RX enlace

    http://www.rxlist.com/cgi/generic/salmeterol.htm

    Salmetedur FDA hoja

    Salmetedur FDA

    Salmetedur MSDS (hoja de seguridad de materiales)

    Salmetedur MSDS

    Salmetedur Sintesis de referencia

    SI Skidmore et al., Patente de EE.UU.. 4.992.474 (1991).

    Salmetedur Peso molecular

    415.566 g/mol

    Salmetedur Punto de fusion

    75.5-76.5 oC

    Salmetedur H2O Solubilidad

    Muy poco soluble

    Salmetedur Estado

    Solid

    Salmetedur LogP

    5.022

    Salmetedur Formas de dosificacion

    Inhaladores de dosis medidas (aerosol), en polvo

    Salmetedur Indicacion

    Para el tratamiento del asma y enfermedad pulmonar obstructiva crónica (EPOC).

    Salmetedur Farmacologia

    Salmeterol es una acción prolongada beta2-adrenérgico (LABA), por lo general sólo se prescribe para el asma persistente grave tras un tratamiento previo con un agonista beta de acción corta como el salbutamol y se prescribe al mismo tiempo con un corticosteroide, como la beclometasona. La principal diferencia notable de salmeterol con salbutamol es que la duración de la acción dura aproximadamente 12 horas en comparación con 4-6 horas de salbutamol. Cuando se usa regularmente todos los días como presecribed, salmeterol inhalados reduce el número y la severidad de los ataques de asma. Sin embargo, no es para su uso para aliviar un ataque de asma que ya ha comenzado. Salmeterol inhalado funciona como otros beta-2 agonistas, provocando broncodilatación mediante la relajación del músculo liso en las vías respiratorias con el fin de tratar la exacerbación del asma. Salmeterol es una acción similar a formoterol, formoterol sin embargo se ha demostrado que tiene un rápido comienzo de acción de salmeterol como resultado de una menor lipofilicidad, y también ha demostrado ser más potente - una dosis de formoterol 12 mg se ha demostrado que es equivalente a una dosis de 50 mg de salmeterol.

    Salmetedur Absorcion

    Debido a la dosis terapéutica pequeños, los niveles sistémicos de salmeterol son muy bajos o indetectables después de la inhalación de dosis recomendadas.

    Salmetedur Toxicidad

    Los síntomas de sobredosis incluyen angina (dolor de pecho), mareo, boca seca, fatiga, síntomas parecidos a la gripe, dolor de cabeza, irregularidades cardiacas, presión arterial alta o baja, azúcar en la sangre, insomnio, calambres musculares, náuseas, nerviosismo, taquicardia, convulsiones y temblores. Por vía oral, no se produjeron muertes en ratas a 1.000 mg / kg (aproximadamente 81.000 veces la dosis máxima recomendada por inhalación al día en adultos y aproximadamente 38.000 veces la dosis máxima recomendada inhalación diaria de los niños sobre una base mg/m2).

    Salmetedur Informacion de Pacientes

    PATIENT INFORMATION

    Patients being treated with SEREVENT DISKUS should receive the following information and instructions. This information is
    intended to aid them in the safe and effective use of this medication. It is not a disclosure of all possible adverse or
    intended effects.

    It is important that patients understand how to use the DISKUS appropriately and how to use SEREVENT DISKUS in relation to
    other asthma or COPD medications they are taking. Patients should be given the following information:

    1. The action of SEREVENT DISKUS may last up to 12 hours or longer. The recommended dosage (1 inhalation twice daily, morning
    and evening) should not be exceeded.

    2. Most patients are able to taste or feel a dose delivered from SEREVENT DISKUS. However, whether or not patients are able to
    sense delivery of a dose, you should instruct them not to exceed the recommended dose of 1 inhalation twice daily, morning and
    evening. You should instruct them to contact you or the pharmacist if they have questions.

    3. SEREVENT DISKUS is not meant to relieve acute asthma or COPD symptoms and extra doses should not be used for that purpose.
    Acute symptoms should be treated with an inhaled, short-acting bronchodilator (the physician should provide the patient with
    such medication and instruct the patient in how it should be used).

    4. Patients should not stop therapy with SEREVENT DISKUS for asthma or COPD without physician/provider guidance since symptoms
    may worsen after discontinuation.

    5. �When used for the treatment of EIB, 1 inhalation of SEREVENT DISKUS should be taken 30 minutes before exercise.

    � Additional doses of SEREVENT should not be used for 12 hours.

    � Patients who are receiving SEREVENT DISKUS twice daily should not use additional SEREVENT for prevention of EIB.

    6. The physician should be notified immediately if any of the following situations occur, which may be a sign of seriously
    worsening asthma or COPD:

    � Decreasing effectiveness of inhaled, short-acting beta2-agonists

    � Need for more inhalations than usual of inhaled, short-acting beta2-agonists

    � Significant decrease in PEF or lung function as outlined by the physician

    � Use of 4 or more inhalations per day of a short-acting beta2-agonist for 2 or more days consecutively

    � Use of more than 1 canister (200 inhalations per canister) of an inhaled, short-acting beta2-agonist in an 8-week period.

    7. SEREVENT DISKUS should not be used as a substitute for oral or inhaled corticosteroids. The dosage of these medications should
    not be changed and they should not be stopped without consulting the physician, even if the patient feels better after initiating
    treatment with SEREVENT DISKUS.

    8. Patients should be cautioned regarding adverse effects associated with beta2-agonists, such as palpitations, chest pain, rapid
    heart rate, tremor, or nervousness.

    9. When patients are prescribed SEREVENT DISKUS, other medications for asthma and COPD should be used only as directed by the
    physician.

    10. SEREVENT DISKUS should not be used with a spacer device.

    11. Patients who are pregnant or nursing should contact the physician about the use of SEREVENT DISKUS.

    12. Effective and safe use of SEREVENT DISKUS includes an understanding of the way that it should be used:

    � Never exhale into the DISKUS.

    � Never attempt to take the DISKUS apart.

    � Always activate and use the DISKUS in a level, horizontal position.

    � Never wash the mouthpiece or any part of the DISKUS. KEEP IT DRY.

    � Always keep the DISKUS in a dry place.

    � Discard 6 weeks after removal from the moisture-protective foil overwrap pouch or after all blisters have been used (when the
    dose indicator reads "0" ), whichever comes first.

    13. For the proper use of SEREVENT DISKUS and to attain maximum benefit, the patient should read and follow carefully the Patient's
    Instructions for Use accompanying the product.

    Salmetedur Organismos afectados

    Humanos y otros mamíferos